BusinessCaldera taps reverse merger to advance TL1A × IL-23 bispecific
Cambridge, Massachusetts-based Caldera Therapeutics has agreed to merge with Synlogic, Inc. (OTC: SYBX) in an all-stock transaction, with the combined...
Read full article →Business
Systematic, data-driven science coverage · Wednesday, July 29, 2026
BusinessMost Read
Business
Adjuvia raises USD 8m for preclinical-stage mitochondrial therapy
Business
AbCellera adds Vertex as latest TCE platform partner in autoimmune disease
Business
Qnovia bets on antimicrobial peptides with exclusive UVA deal
Business
LB Pharma raises USD 150m to expand LB-102 zinto three neuropsychiatric indications
Development
GSK/Hansoh's B7-H3 ADC set for China filing after hitting Phase III endpoint in osteosarcoma
Business
2h agoAdjuvia raises USD 8m for preclinical-stage mitochondrial therapy
San Francisco-based Adjuvia Therapeutics has closed an USD 8 million Series Seed financing to advance its lead mitochondrial disease therapy candidate,...
Business
3h agoAbCellera adds Vertex as latest TCE platform partner in autoimmune disease
Vancouver-based AbCellera Biologics (Nasdaq: ABCL) has announced a collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to discover and develop...
Business
3h agoQnovia bets on antimicrobial peptides with exclusive UVA deal
Irvine, California-based Qnovia, Inc. has secured a worldwide exclusive license to a preclinical antimicrobial peptide, designated D8, from the University...
Business
3h agoLB Pharma raises USD 150m to expand LB-102 zinto three neuropsychiatric indications
New York-based LB Pharmaceuticals Inc (Nasdaq: LBRX) has announced a USD 150 million private placement, with the proceeds earmarked primarily to expand its...
Business
6h agoGSK accelerates 20-plus Phase III starts through GBP 1.9b savings program
GSK plc's Q2 2026 earnings call, held on July 28, 2026, revealed one of the most aggressive late-stage pipeline acceleration programs the company has...
Business
8h agoBasilea secures USD 30m BARDA tranche to advance fosmanogepix Phase III trials
Switzerland-based Basilea Pharmaceutica Ltd (SIX: BSLN) announced a USD 30 million non-dilutive funding tranche from the Biomedical Advanced Research and...
Business
11h agoCORE launches with a portfolio licensed from Eisai plus USD 21m in financing
Boston-based CORE Biomedicine has secured exclusive global rights to a portfolio of preclinical oncology programs from Japan-based Eisai Co., Ltd. (TYO:...
Business
1d agoClaris Bio raises USD 118m to advance first-ever pharmacologic therapy for limbal stem cell deficiency
Jersey City, New Jersey-based Claris Biotherapeutics, Inc. has closed a USD 118 million Series B financing to advance CSB-001 (oremepermin alfa ophthalmic...
Business
1d agoYarrow completes reverse merger with VYNE, enters Phase II with TSHR antibody
New Haven, Connecticut-based Yarrow Bioscience, Inc. (Nasdaq: YARW) has closed its reverse merger with VYNE Therapeutics and simultaneously initiated dosing...
Business
1d agoHarbour Bio pairs Harbour Mice platform with Sinopharm to develop biologics across oncology and inflammation
HBM Holdings Limited (HKEX: 02142) has entered a strategic collaboration with China National Pharmaceutical Group Co., Ltd. (Sinopharm) to establish a joint...
Business
2d agoApnimed seeks USD 150m IPO ahead of February 2027 FDA decision on sleep apnea drug
Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based company whose sole clinical asset is an NDA-stage oral therapy for obstructive sleep apnea...
Business
2d agoRoche Q2'26: Divarasib outlook rises after Phase III win as obesity pipeline advances
Roche's Q2 2026 earnings call, held on July 23, 2026, was dominated by a positive Phase III readout for divarasib in KRAS G12C-positive non-small cell lung...
Business
2d agoEntera Bio raises USD 275m to fund Phase III trial of oral osteoporosis therapy EB613
Israel-based Entera Bio Ltd. (Nasdaq: ENTX) announced an oversubscribed private placement of approximately USD 275 million to fully fund the Phase III...
Business
2d agoRA Capital-backed Oak Hill to go public in USD 175m SPAC deal
Cambridge, Massachusetts-based Oak Hill Bio has agreed to merge with Research Alliance Corporation III (Nasdaq: RACC), a special purpose acquisition company...
Business
2d agoArgenx acquires Forte for USD 2.2b to add first-in-class CD122 antibody to immunology pipeline
Netherlands-based argenx (Euronext & Nasdaq: ARGX) has agreed to acquire Dallas-based Forte Biosciences, Inc. (Nasdaq: FBRX) for USD 77 per share in cash,...
The AllSci Brief
Systematic R&D and deal news. Daily.